Inozyme Pharma (INZY) Q2 2024 earnings summary

Executive summary

• Advanced INZ-701 clinical programs in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, with positive topline data and regulatory milestones, including FDA Fast Track designation for ABCC6 Deficiency in July 2024.

• Completed enrollment in key trials and reported sustained safety and efficacy data; pivotal trial topline data for pediatric ENPP1 Deficiency expected in H2 2025.

• Published preclinical data supporting INZ-701's potential in PPi-Adenosine Pathway diseases.

Financial highlights

• Net loss of $27.0 million ($0.44 per share) for Q2 2024, compared to $15.6 million ($0.35 per share) in Q2 2023.

• Cash, cash equivalents, and short-term investments totaled $144.5 million as of June 30, 2024, down from $188.6 million at year-end 2023.

• Operating expenses rose to $27.7 million in Q2 2024 from $16.4 million in Q2 2023, driven by increased R&D and personnel costs.

• No revenue generated; operations funded by equity offerings, debt, and milestone payments.

• Total assets were $155.7 million and total liabilities $61.3 million as of June 30, 2024.

Outlook and guidance

• Existing cash resources expected to fund operations into Q4 2025; additional capital will be needed beyond that period.

• Anticipates increased expenses as clinical programs expand and commercialization preparations begin.

• Key milestones: ENERGY 3 enrollment completion in Q3 2024, interim ENERGY 1 and SEAPORT 1 data in Q4 2024, and topline ENERGY 3 data in H2 2025.

• Pivotal trial initiation for pediatric ABCC6 Deficiency planned for Q1 2025, subject to regulatory review and funding.